Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states. The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes. This ...
Jackson Center, PA, April 11, 2022 – Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of nonfungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc. Halberd is currently in negotiations to engage a team of experts in ...
Jackson Center, PA, March 16, 2022 – Halberd Corporation (OTC-PINK: "HALB") announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and ...
Jackson Center, PA, March 8, 2022 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. Chester R. Cooper has joined its technical team. Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University. Dr. Cooper has been a valuable resource in Halberd’s work at ...
Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies. The results are shown ...
Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens. See Table Below. This could lead to ...
Tau buildup in the brain is linked to Alzheimer’s and other neurodegenerative diseases. Jackson Center, PA, February 8, 2022 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid (CSF) in less than 20 minutes with its patented extracorporeal laser exposure process. Excess Tau in CSF ...
Tau has been shown to be important in the development of Alzheimer’s Disease. Eradication of tau accomplished without reducing levels of non-target cytokine. Jackson Center, PA, February 1, 2022 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to selectively reduce and control the level of one element in a heterogeneous mixture containing two elements ...
Jackson Center, PA, January 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) First of all I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year! 2021 OVERVIEW AND ACHIEVEMENTS Halberd continued its R&D strategy to focus on biomedical areas where: There is ...
Halberd to bid on Additional Federal Contracts with the Federal Government Jackson Center, PA, January 5, 2022 – Halberd Corporation (OTC PINK:HALB) is now registered with the Federal Government’s System for Award Management allowing Halberd to bid on Federal contracts and conduct business with the Federal government in the areas of Research and Development in ...